European Annals of Allergy and Clinical Immunology 2017-Nov
Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Länken sparas på Urklipp
Nyckelord
Abstrakt
UNASSIGNED
Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.